Evidence map›Paper›PMID 33825359›Full record

ArticleJournal of gynecologic oncology2021

The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee.

Masae Ikeda, Masako Shida, Shogo Shigeta, Satoru Nagase, Fumiaki Takahashi, Wataru Yamagami, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki, Mikio Mikami

Open access · diamondAbstract read
In one paragraph

Article in Journal of gynecologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Masae IkedaDepartment of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan. ikedam@tokai-u.jp.ORCID 0000-0002-7289-4379
Masako ShidaDepartment of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan.ORCID 0000-0003-2359-5003
Shogo ShigetaDepartment of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.ORCID 0000-0001-8447-8826
Satoru NagaseDepartment of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan.ORCID 0000-0001-5212-1128
Fumiaki TakahashiClinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan.ORCID 0000-0001-9201-1089
Wataru YamagamiDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0003-3925-6057
Hidetaka KatabuchiDepartment of Obstetrics and Gynecology, Kumamoto University Faculty of Life Sciences, Kumamoto, Japan.ORCID 0000-0002-2403-6134
Nobuo YaegashiDepartment of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.ORCID 0000-0003-2521-039X
Daisuke AokiDepartment of Obstetrics and Gynecology, Kumamoto University Faculty of Life Sciences, Kumamoto, Japan.ORCID 0000-0002-9596-8326
Mikio MikamiDepartment of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan.ORCID 0000-0002-7496-3518
Tokai University · JPKumamoto University · JPTohoku University · JPKeio University · JPTohoku University Hospital · JPYamagata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe Japan Society of Gynecologic Oncology published the first guidelines for the treatment of cervical cancer in 2007. The aim of this research was to evaluate the influence of the introduction of the first guideline on clinical trends and outcomes of patients with early-stage cervical cancer who underwent surgery.

methodsThis analysis included 9,756 patients who were diagnosed based on the pathological Tumor-Node-Metastasis (pTNM) classification (i.e., pT1b1, pT1b2, pT2b and pN0, pN1, pNX) and received surgery as a primary treatment between 2004 and 2009. Data of these patients were retrospectively reviewed, and clinicopathological trends were assessed. The influence of the introduction of the guideline on survival was determined by using a competing risk model.

resultsFor surgery cases, the estimated subdistribution hazard ratio (HR) by the competing risk model for the influence of the guideline adjusted for age, year of registration, pT classification, pN classification, histological type, and treatment methods was 1.024 (p=0.864). Following the introduction of the first guideline in 2007, for patients with lymph node metastasis, the use of chemotherapy (CT) as a postsurgical therapy increased, whereas that of concurrent chemoradiotherapy (CCRT)/radiotherapy (RT) decreased (p<0.010). For pN1 cases, the estimated subdistribution HR by the competing risk model for the influence of the guideline was 1.094 (p=0.634). There was no significance in the postsurgical therapy between CT and CCRT/RT (p=0.078).

conclusionsSurvival of surgical cases was not improved by the introduction of the guidelines. It is necessary to consider more effective postsurgical therapy for high-risk early-stage cervical cancer.

Indexed as

Uterine Cervical NeoplasmsFemaleHumansJapanLymphatic MetastasisLymph NodesNeoplasm StagingRetrospective StudiesCervical CancerGuideline EvaluationLymph Node MetastasisPostsurgical Adjuvant TherapySurgery

Identifiers

PMID33825359
PMCPMC8039172
OpenAlexW3139034286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.